Invent Medical Corporation received FDA Emergency Use Authorization for HFT 150 Hospital System.
This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of HFT 150 and accessories during the COVID-19 pandemic is terminated under section 564(b)(2) of the Act or the EUA is revoked under section 564(g) of the Act.

Nasal heated high flow therapy has been peer reviewed and proven to provide a mode of therapy that meets or exceeds the demands of the patient suffering from respiratory insufficiency and hypoxia. Moreover, the patient may subjectively feel less flow-hungry and demonstrate decreased work of breathing thereby reducing anxiety and improvement in their blood oxygen saturation thus reducing or eliminating hypoxia. The level of heated high flow and oxygen is directly proportional to the reduction in fraction of dead space ventilation, clearance of exhaled carbon dioxide, Sp02 and improvement in ventilatory efficiency.

What Is The HFT150?
Contact Our Team


Request a Demo HFT Features

HFT 150 Features

The HFT 150’s built-in anti-bacterial and anti-viral filter protects the device.

All Invent devices are equipped with an integrated heated humidifier and heated wire tubing. This integrated design saves space and makes it easier for the clinician to setup.

The HFT 150 offers an air/oxygen mixer integrated into the device, thus saving space and making it easy to setup. This feature allows the clinician to adjust the FiO2 from 21 to 100% via a touch screen.

The HFT 150 is equipped with an internal battery. This feature allows uninterrupted therapy for the patient.

The HFT 150 has a remote alarm port used to connect with nurse call systems.

An optional stand is available.

The HFT 150 offers an external Nonin Pulse Oximeter to monitor continuous blood oxygen saturation.

Meet the Invent Medical Team

Invent Medical is led by industry experts with combined relevant experience of more than 300 years.

Management Team

Sam Chang, CEO

Over 33 years in research, product Development, Marketing, Executive Management. Proven leadership demonstrated in highly respected and industry-leading companies such as ResMed, Invacare, Respironics, and Puritan-Bennett as well as startups. Holds several key patents in Respiratory Care. Innovative, cross-platform thinker & inventor. BSME from Yonsei University; MSME from the University of Texas, Arlington. Post-graduate studies in Mechanical, Electrical Engineering, and Microcomputers at various institutions.

George Jackson, CFO

Served as President / CEO of many fitness entities and as CFO of a small public company.  Owned and operated over 30 fitness centers in the USA and Asia. Currently, owner of the fitness brand TG The Gym with location in Vista and San Diego, California, and a partner in Muscle Sport Productions, which promotes NPC and IFBB shows in Northern and Central California. Board of directors of the Mitchell Thorp Foundation, which serves children with life-threatening diseases and disorders and produces events to raise money locally for this charity. BS in Accounting at the University of Southern California. Currently an active Certified Public Accountant in CA

Ron Richard, Sr. VP Sales & Marketing

Mr. Richard has been employed in the medical industry for over thirty-five years and has extensive knowledge and experience in respiratory, pulmonary and sleep medicine. He began his medical career working in a respiratory department at a large teaching hospital in the Midwest. Upon leaving the medical center, he became involved in owning and operating home care companies, sleep laboratories, manufacturers and distribution businesses. In addition to these experiences he was instrumental in developing and designing several products used in the treatment and diagnosis of chronic health care conditions. He has launched over 40 major products resulting in sales over $1B.
He has held senior level positions with Nellcor Puritan Bennett, Thermo Electron, ResMed, Qualcomm, and several other companies in the area of sleep and respiratory care sectors.
He graduated from Baker University with a degree in Business Administration. He holds certificates in respiratory care and emergency medicine. He has been awarded 15 patents and multiple industry awards due to his focus and dedication to improving health care outcomes.

George Ng, Executive Advisor

George Ng, a partner at PENG Life Science Ventures (PENG LSV), is a seasoned life sciences industry executive. He has founded and/or led multiple companies, including Scilex Pharmaceuticals, Inc., where he was Co-Founder and President, Business, and led the company through development, clinical trials, NDA submission, FDA approval, $140 million financing and commercial launch of the company’s first FDA-approved drug product. Mr. Ng has also held various other senior management positions, including Board Director, Managing Director, Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded and private, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, Mr. Ng helped lead the development and commercialization efforts and launches of multiple pharmaceutical drug products. Previously, in private practice, Mr. Ng was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair. Additionally, Mr. Ng is a current member of the Board of Directors for multiple companies, including iActa Pharmaceuticals, Inc., Inflammatory Response Research, Inc. (IRR) and Calidi Biotherapeutics, Inc. Mr. Ng was also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was previously appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. In addition, he is a frequent speaker and noted authority on legal, compliance and business issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical, legal and compliance congresses and conferences. Among his multiple awards and commendations, Mr. Ng is a recipient of the 2015 Outstanding 50 Asian Americans in Business Award, past recipient of M&A Advisor’s Top 40 Under 40 Award (in 2012) and nominee for the Orange County Business Journal’s Inaugural General Counsel Awards (in 2010); and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed. Mr. Ng earned a Juris Doctor (J.D.) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (B.A.S.) dual degree in Biochemistry & Economics from the University of California, Davis.

Medical Advisory Board

David Willms, MD

Baylor College of Medicine and practices Pulmonary and Critical Care Medicine. Internship, residency, and chief residency in Internal Medicine at the University of Texas Health Science Center in San Antonio, Fellowship in Pulmonary & Critical Care Medicine at the University of California, San Diego. Currently Director of the Critical Care Service at Sharp Memorial Hospital in San Diego, California, and is the Medical Director of the Grossmont College Respiratory Therapy Program. Served as Chief of Internal Medicine, Sharp Memorial Hospital, Chief of Staff at Vencor-San Diego, Medical Director of Lung Transplantation, and Director of Adult Cystic Fibrosis services and Director of Pulmonary Rehabilitation at Sharp Memorial Hospital. Board-certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine, and is a member of numerous professional societies. Served on the editorial boards of ASAIO Journal, the official publication of the American Society for Artificial Internal Organs, and Respiratory Care, and the World Journal of Critical Care. Dr. Willms researches and publishes articles on respiratory failure, acute respiratory distress syndrome, sepsis, heliox therapy, and extracorporeal life support. In 2010 – 2011, he was the key physician contributor to the San Diego Patient Safety Council initiative on Reducing the Incidence and Mortality of Sepsis. Spoke nationally and internationally on various critical care topics.

Brian Carlin, MD

Brian Carlin, MD, FCCP, MAACVPR, FAARC, is currently in the practice of pulmonary, critical care, and sleep medicine in Pittsburgh, Pennsylvania, and is the medical director of pulmonary rehabilitation for Lifeline Therapy for Pulmonary Rehabilitation. He is a former training program director of the pulmonary critical care medicine fellows. Dr. Carlin has been active in multiple national and regional organizations being a past president of the American Association of Cardiovascular and Pulmonary Rehabilitation as well as the Association of Pulmonary and Critical Care Medicine Program Directors. He is the current chairperson of the National Lung Health Education Program and is a member of the board of the National Board for Respiratory Care. He is actively involved in clinical research projects in the fields of rehabilitation and COPD readmission reduction programs. He has helped to create successful educational programs centered on the performance of spirometry and the use of inhaled medication delivery devices.

Nick Hill, MD

Nicholas S. Hill, MD, is professor of medicine at Tufts University School of Medicine and chief of the pulmonary, critical care, and sleep division at Tufts Medical Center in Boston. He received his medical degree from Dartmouth Medical School in New Hampshire and completed cardiovascular and pulmonary fellowships from University of Massachusetts Medical Center and Boston University School of Medicine, respectively.
Dr. Hill's primary research interests include the role of angiogenic factors in pulmonary vascular biology, therapeutic approaches for clinical pulmonary hypertension, and evaluating ways of delivering and testing the efficacy of noninvasive ventilation. Dr. Hill is the author or coauthor of more than 200 articles in peer-reviewed journals, such as the American Journal of Physiology, Respiratory Medicine and Critical Care Medicine. He is a past president of the American Thoracic Society and a member of the American College of Chest Physicians, American Association for the Advancement of Science, and Pulmonary Hypertension Association.
Dr. Hill served as president of the American Thoracic Society in 2011-2012.

Angela King

Our Mission

Invent Medical designs, manufactures, and markets respiratory care devices used in home care and institutional settings which covers the recovery, rehabilitation and respiratory needs of patients.

Value Proposition

Invent Medical has developed platform technology focused on delivering best in class therapy with ease of use at a price every home care dealers and hospitals can afford.

Contact Form

Invent Medical is getting ready to launch a revolutionary respiratory product known as the HFT150.
Please, tell our team a little bit more information about yourself and your medical needs.
Request more information or a product demo.
Thank you & we look forward to assisting you.